These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1095 related articles for article (PubMed ID: 8233650)
1. [Expression of P53 protein in cutaneous melanoma]. Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650 [TBL] [Abstract][Full Text] [Related]
2. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions. Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642 [TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. Ross DA; Wilson GD Br J Surg; 1997 Jun; 84(6):803-7. PubMed ID: 9189093 [TBL] [Abstract][Full Text] [Related]
4. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma. Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996 [TBL] [Abstract][Full Text] [Related]
5. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717 [TBL] [Abstract][Full Text] [Related]
6. PUMA expression is significantly reduced in human cutaneous melanomas. Karst AM; Dai DL; Martinka M; Li G Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057 [TBL] [Abstract][Full Text] [Related]
7. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887 [TBL] [Abstract][Full Text] [Related]
8. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. Tchernev G; Orfanos CE J Cutan Pathol; 2007 Mar; 34(3):247-56. PubMed ID: 17302609 [TBL] [Abstract][Full Text] [Related]
10. p53 Protein expression in nevi and melanomas. Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076 [TBL] [Abstract][Full Text] [Related]
11. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma. Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918 [TBL] [Abstract][Full Text] [Related]
12. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. Li Q; Murphy M; Ross J; Sheehan C; Carlson JA J Cutan Pathol; 2004 Nov; 31(10):633-42. PubMed ID: 15491322 [TBL] [Abstract][Full Text] [Related]
13. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Talve L; Kainu J; Collan Y; Ekfors T Pathol Res Pract; 1996 Aug; 192(8):825-33. PubMed ID: 8897518 [TBL] [Abstract][Full Text] [Related]
15. Expression of mutant p53 in melanoma. Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861 [TBL] [Abstract][Full Text] [Related]
16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331 [TBL] [Abstract][Full Text] [Related]
17. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Ross DA; Wilson GD Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382 [TBL] [Abstract][Full Text] [Related]
18. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891 [TBL] [Abstract][Full Text] [Related]
19. Analysis of p53 in human cutaneous melanoma cell lines. Montano X; Shamsher M; Whitehead P; Dawson K; Newton J Oncogene; 1994 May; 9(5):1455-9. PubMed ID: 8152807 [TBL] [Abstract][Full Text] [Related]
20. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]